Anterior Uveitis - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anterior Uveitis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Anterior Uveitis - Pipeline Review, H1 2016', provides an overview of the Anterior Uveitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
- The report reviews pipeline therapeutics for Anterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Anterior Uveitis therapeutics and enlists all their major and minor projects
- The report assesses Anterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Anterior Uveitis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anterior Uveitis Overview 6
Therapeutics Development 7
Pipeline Products for Anterior Uveitis - Overview 7
Anterior Uveitis - Therapeutics under Development by Companies 8
Anterior Uveitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Anterior Uveitis - Products under Development by Companies 12
Anterior Uveitis - Companies Involved in Therapeutics Development 13
Aciont Inc. 13
Aldeyra Therapeutics, Inc. 14
Delenex Therapeutics AG 15
EyeGate Pharmaceuticals, Inc. 16
Kineta, Inc. 17
Neuroptis Biotech 18
Virogenomics BioDevelopment, Inc. 19
Anterior Uveitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
dalazatide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
dexamethasone acetate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
dexamethasone sodium phosphate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DLX-105 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
LME-636 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NOP-3 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NS-2 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Recombinant Peptides to Modulate TCR for Uveitis - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Anterior Uveitis - Recent Pipeline Updates 42
Anterior Uveitis - Dormant Projects 50
Anterior Uveitis - Discontinued Products 51
Anterior Uveitis - Product Development Milestones 52
Featured News & Press Releases 52
Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437 52
Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis 52
May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis 53
Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial 53
Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial 54
Mar 19, 2015: Kineta's ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases 54
Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program 54
Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences 55
Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis 55
Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Anterior Uveitis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Anterior Uveitis - Pipeline by Aciont Inc., H1 2016 13
Anterior Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H1 2016 14
Anterior Uveitis - Pipeline by Delenex Therapeutics AG, H1 2016 15
Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016 16
Anterior Uveitis - Pipeline by Kineta, Inc., H1 2016 17
Anterior Uveitis - Pipeline by Neuroptis Biotech, H1 2016 18
Anterior Uveitis - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Anterior Uveitis Therapeutics - Recent Pipeline Updates, H1 2016 42
Anterior Uveitis - Dormant Projects, H1 2016 50
Anterior Uveitis - Discontinued Products, H1 2016 51